Business   

Ranbaxy recalls Gebapentin tablets

In a setback to Ranbaxy Laboratories, the U.S. drug regulator USFDA has directed the company to recall as many as 7.32 crore Gebapentin tablets of 600 and 800 mg strengths. Gebapentin tablets are prescribed to treat nerve pain.

Printer friendly page  
Send this article to Friends by E-Mail

Stories in this Section

IndusInd Bank weighing options to shore up capital
Currency futures trading for residents mooted
Tea industry: XI Plan outlay cut to Rs. 800 crore
Essar Oil plans to treble capacity
Inflation rate rises to 3.11 per cent
Ranbaxy recalls Gebapentin tablets
Vestas RRB enters Canadian market
New norms for telcos on dues recovery
Reliance Jewels makes debut
Shalimar Paints to acquire a company in South
Focus shifts to mid-cap stocks
Wastes can yield 2,500 MW energy, says study
Exchange Rates
Bullion Rates
Murugappa plans life insurance foray
BoB to foray into life insurance
Onion export restriction withdrawn
Forex reserves up $3.6 billion
Injunction against Godrej soap ad
Surana ties up with Beijing Shougang
Refex board approves Rs. 200 cr. FCCB issue
Satyam to launch SaaS for SMEs
Bajaj Allianz Life introduces CenturyPlus
Website for Indian business opportunities

Copyright © 2007, The Hindu. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu